Key Insights

Highlights

Success Rate

78% trial completion

Research Maturity

51 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

13.3%

14 terminated out of 105 trials

Success Rate

78.5%

-8.0% vs benchmark

Late-Stage Pipeline

16%

17 trials in Phase 3/4

Results Transparency

16%

8 of 51 completed with results

Key Signals

8 with results78% success14 terminated

Data Visualizations

Phase Distribution

64Total
Not Applicable (22)
P 1 (8)
P 2 (17)
P 3 (13)
P 4 (4)

Trial Status

Completed51
Unknown29
Terminated14
Withdrawn6
Recruiting3
Suspended1

Trial Success Rate

78.5%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (105)

Showing 20 of 20 trials
NCT05976581Not ApplicableCompleted

Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients

NCT04305457Phase 2Terminated

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

NCT05123755Phase 2Recruiting

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

NCT04340466CompletedPrimary

French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study

NCT04422613Not ApplicableCompletedPrimary

Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia

NCT06134492Phase 3RecruitingPrimary

Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL

NCT01271842Completed

Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study

NCT04830800Phase 1Completed

A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)

NCT05290441Not ApplicableCompletedPrimary

Evaluation of Postmortem Pulmonary Interstitial Fibrosis Severity and EGFR Positivity in Covid-19 Pneumonia

NCT05077917Phase 3Terminated

Cromolyn Sodium for Treatment of COVID-19 Pneumonia

NCT04429555Phase 2CompletedPrimary

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

NCT04764929Not ApplicableTerminated

Pediatric Helmet CPAP Pilot Study

NCT06501599RecruitingPrimary

AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes

NCT04878055Phase 3CompletedPrimary

Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.

NCT06296693Not ApplicableNot Yet Recruiting

Diagnostic Accuracy of Pocket-size Lung Ultrasound in Pneumonia Etiology and Complications in Hospitalized Children

NCT05321433Completed

Tobacco Use and the Risk of COVID-19 and Adverse Outcomes

NCT04914832Phase 4Completed

Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death

NCT04629703Phase 3Completed

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

NCT04727775Completed

Antiviral Drugs on the Treatment of SARS-CoV-2

NCT05808361Not ApplicableCompleted

Rehabilitation Treatment of Patients With COVID-19

Scroll to load more

Research Network

Activity Timeline